Compare MGTX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGTX | AMPH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.1M | 971.8M |
| IPO Year | 2018 | 2005 |
| Metric | MGTX | AMPH |
|---|---|---|
| Price | $14.98 | $19.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $24.57 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 1.1M | 571.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $81,391,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $141.38 | $6.90 |
| Revenue Next Year | N/A | $4.64 |
| P/E Ratio | ★ N/A | $140.07 |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $6.62 | $16.65 |
| 52 Week High | $14.42 | $31.26 |
| Indicator | MGTX | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 78.12 | 51.55 |
| Support Level | $7.21 | $18.57 |
| Resistance Level | N/A | $20.13 |
| Average True Range (ATR) | 0.90 | 0.96 |
| MACD | 0.35 | -0.02 |
| Stochastic Oscillator | 91.10 | 49.47 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.